

AVANIR PHARMACEUTICALS

Form 8-K

May 08, 2003

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

---

**FORM 8-K  
CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 8, 2003

**AVANIR PHARMACEUTICALS**

---

(Exact Name of Registrant as Specified in Charter)

California

001-15803

33-0314804

---

(State of Incorporation or Organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

11388 Sorrento Valley Road, Suite 200, San Diego, California

92121

---

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 622-5200

\_\_\_\_\_  
NOT APPLICABLE

---

(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 7. Financial Statements and Exhibits.

Item 9. Regulation FD Disclosure.

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 7. Financial Statements and Exhibits.**

**Exhibit**

99.1 Press release, dated May 8, 2003

**Item 9. Regulation FD Disclosure.**

On May 8, 2003, AVANIR Pharmaceuticals issued a press release announcing its results of operations for the quarter ended March 31, 2003. A copy of the press release is furnished herewith as Exhibit 99.1.

**This information furnished under *Item 9. Regulation FD Disclosure* and the exhibit attached hereto are intended to be furnished under *Item 12. Results of Operations and Financial Condition* in accordance with SEC Release 33-8216.**

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 8, 2003

AVANIR PHARMACEUTICALS

By: /s/ Gregory P. Hanson

---

Gregory P. Hanson  
Chief Financial Officer

**Table of Contents**

**EXHIBIT INDEX**

| <b>Exhibit No</b> | <b>Description</b>               |
|-------------------|----------------------------------|
| 99.1              | Press release, dated May 8, 2003 |